A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine.
We report a 33-year-old woman with haemodialysis-associated pseudoporphyria successfully responding to treatment with oral N-acetylcysteine. We briefly review the current literature on bullous skin disorders in end-stage renal disease, and compare and contrast the pathogenesis of pseudoporphyria and porphyria cutanea tarda in this context. We also discuss the antioxidant properties and clinical applications of N-acetylcysteine, including the treatment of haemodialysis-associated pseudoporphyria.
Cooke
N S
NS
Department of of Dermatology, Belfast City Hospital, Belfast, UK. nicolacooke36@hotmail.com
McKenna
K
K
D000111:Acetylcysteine / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D017119:Porphyria Cutanea Tarda / Q000188:drug therapy / Q000209:etiology; D011164:Porphyrias / Q000188:drug therapy*; D006435:Renal Dialysis / Q000009:adverse effects*
D016166:Free Radical Scavengers; D000111:Acetylcysteine